PerformanceResearch Phase

Follistatin-344

Intramuscular injection, Gene delivery

Overview

Follistatin-344 is a 344-amino acid glycoprotein that functions as a binding protein and endogenous antagonist of myostatin and other members of the TGF-beta superfamily. By sequestering myostatin, follistatin removes inhibitory signals that limit skeletal muscle growth, thereby permitting increased muscle fiber hypertrophy and hyperplasia.

Mechanism of Action

The peptide also modulates activin and bone morphogenetic protein signaling pathways..

Research Summary & Key Findings

Preclinical studies in animal models have demonstrated substantial increases in muscle mass following follistatin gene delivery or protein administration. Human clinical investigation has been extremely limited, with no controlled trials published as of current literature review. Safety concerns regarding off-target effects on reproductive and metabolic pathways remain unaddressed.

Clinical Status

Research Phase

Follistatin-344 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intramuscular injectionGene delivery

Related Peptides in Performance

Find a Provider

Find a verified provider who offers Follistatin-344 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Follistatin-344.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.